Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gandou Fumu granule is a Traditional Chinese Medicine (TCM) formulation developed by the **First Affiliated Hospital of Anhui University of Chinese Medicine** (specifically the Institute of Neurology) for the treatment of **Wilson's disease** (hepatolenticular degeneration). The formula is designed based on the TCM principle of "supporting the wood" (liver) and "strengthening the earth" (spleen) to address the underlying pathology of copper accumulation and liver-spleen disharmony. It is primarily used as an in-hospital preparation in China. Clinical research suggests that the granules, often used in conjunction with standard chelating agents like penicillamine or dimercaptosuccinic acid, help improve liver function, reduce clinical symptoms, and potentially modulate copper metabolism by influencing transporters such as ATP7B and ceruloplasmin levels. The preparation typically consists of a complex mixture of botanical extracts including *Pseudostellaria heterophylla*, *Atractylodes macrocephala*, and *Poria cocos*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gandou Fumu granule (Anhui University of Chinese Medicine).